Analysis
Scribe Therapeutics priced an upsized initial public offering at $15.00 per share -- the top of its marketed range -- raising $128.7 million gross, and began trading on Nasdaq under the ticker SCTX on July 24. It's the first gene-editing biotech IPO to price in more than two years, a notably dry stretch for the category following a broader biotech-financing slowdown.
The offering carried a genuine strategic validation signal: Sanofi participated in a concurrent private placement, purchasing 500,000 shares at the same $15.00 price, giving Scribe a pharma anchor investor alongside its public-market debut rather than relying purely on retail and institutional demand.
Scribe develops in vivo CRISPR gene-editing therapies targeting cardiometabolic disease, including STX-1200 for cholesterol reduction and STX-1400 for triglycerides -- large, well-established markets currently served by drugs like PCSK9 inhibitors, giving Scribe's pipeline a clearer commercial pathway than many earlier-stage gene-editing companies pursuing rarer indications.
The pricing lands as a notable outlier against the broader week's IPO and market tape: SpaceX shares fell below their own $135 issue price for the first time since its June IPO, and the broader tech-led selloff triggered by Tesla and Alphabet's earnings spread into Asian markets on the same Friday Scribe began trading. An upsized, top-of-range biotech pricing in that environment suggests investors are drawing a sharper line between AI-infrastructure valuations, which are facing real scrutiny, and differentiated biotech pipelines with large addressable markets and strategic pharma validation.
For healthcare and biotech investors, Scribe's pricing is an early test of whether gene-editing as a category can attract public-market capital again after a multi-year drought. Watch Scribe's aftermarket trading performance over its first several sessions, and whether other gene-editing and cell-therapy companies in the private pipeline use this pricing as a signal to accelerate their own IPO timelines.
